CDC-Nigeria, Centers for Disease Control and Prevention, Abuja.
Clin Infect Dis. 2012 May;54 Suppl 4:S375-80. doi: 10.1093/cid/cir1064.
This report describes a pilot study, conducted in Nigeria, of the World Health Organization protocol for monitoring human immunodeficiency virus (HIV) drug resistance (HIVDR) and associated program factors among patients receiving first-line antiretroviral therapy (ART). In 2008, 283 HIV-infected patients starting ART were consecutively enrolled at 2 ART clinics in Abuja. Twelve months after ART initiation, 62% were alive and on first-line ART, 3% had died, 1% had transferred out of the program, and 34% were lost to follow-up. Among patients on first-line ART at 12 months, 90% had viral suppression. However, in view of the high loss to follow-up rate (34%), strategies for patient retention and tracking are critical to minimize possible HIVDR and optimize treatment outcomes.
本报告描述了在尼日利亚进行的一项试点研究，该研究采用了世界卫生组织（WHO）监测人类免疫缺陷病毒（HIV）耐药性（HIVDR）和相关方案因素的方案，研究对象为接受一线抗逆转录病毒治疗（ART）的患者。2008 年，阿布贾的 2 家 ART 诊所连续纳入了 283 名开始接受 ART 的 HIV 感染者。在 ART 启动后 12 个月时，62%的患者仍然存活并接受一线 ART 治疗，3%的患者死亡，1%的患者转出该项目，34%的患者失访。在 12 个月时接受一线 ART 治疗的患者中，90%的患者病毒得到了抑制。然而，鉴于高失访率（34%），患者保留和跟踪策略对于最大限度地减少可能的 HIVDR 和优化治疗结果至关重要。
